Inotiv Earnings Reports

Inotiv delivered a strong third quarter in fiscal 2025, with revenue increasing by 23.5% year-over-year to $130.7 million, primarily due to growth in NHP-related products and services within the RMS segment and increased toxicology and biotherapeutic services in the DSA segment. The company also significantly reduced its operating loss from $20.8 million in Q3 FY 2024 to $5.7 million in Q3 FY 2025, largely due to improved RMS operating income and the absence of a prior year charge related to a DOJ agreement.

Inotiv, Inc. reported a 4.4% increase in total revenue to $124.3 million for Q2 FY 2025, primarily due to a 9.1% increase in Research Models and Services (RMS) revenue. The company significantly reduced its consolidated net loss from $48.1 million in Q2 FY 2024 to $14.9 million in Q2 FY 2025 and improved its Adjusted EBITDA to $8.0 million.

Inotiv reported a decrease in revenue for Q1 2025, driven by lower performance in both its RMS and DSA segments. The company experienced a net loss, although they enhanced liquidity through a common share issuance.

Inotiv reported a 7.3% decrease in revenue for Q4 2024, totaling $130.4 million, and a net loss of $18.9 million. The revenue decline was primarily driven by decreases in both Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. Despite the challenges, the company completed site optimization plans, saw some recovery in NHP sales, and amended its credit agreement.

Inotiv's Q3 2024 revenue decreased by 32.8% to $105.8 million compared to Q3 2023, primarily due to a decline in Research Models and Services (RMS) revenue. The company reported a net loss of $26.1 million, compared to a net income of $0.4 million in the same period last year. Despite the challenges, Inotiv completed site optimization projects and saw the conclusion of certain government investigations.

Inotiv reported a 21.5% decrease in revenue for Q2 2024, totaling $119.0 million, primarily due to a significant drop in Research Models and Services (RMS) revenue. The company faced a consolidated net loss of $48.1 million, which included a $26.5 million charge related to an agreement in principle with the U.S. Department of Justice. The company withdrew its fiscal year 2024 outlook due to NHP revenue impact and uncertainty in customer demand.

Inotiv reported a 10.3% increase in revenue to $135.5 million for Q1 FY 2024, driven by growth in both DSA and RMS segments. The company's net loss significantly improved to $15.8 million compared to $86.9 million in the same period last year. Adjusted EBITDA also saw a positive shift, reaching $9.6 million.

Inotiv reported Q4 FY2023 financial results, with revenue at $140.7 million, a decrease of 6.5% compared to Q4 FY2022. The company's net loss was $8.7 million, an improvement from the $243.6 million loss in the same period last year. Adjusted EBITDA was $23.7 million, up from $18.3 million in Q4 FY2022.

Inotiv reported a decrease in revenue for Q3 FY 2023 compared to Q3 FY 2022, driven by lower revenue in both the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. However, the company achieved consolidated net income compared to a net loss in the same period last year. The company is focused on completing integration projects, optimizing infrastructure, and right-sizing its global footprint.

Inotiv reported increased revenue driven by growth in both DSA and RMS segments. However, the company experienced a net loss due to higher operating expenses, including depreciation, amortization, stock compensation, legal, and third-party fees. The company is confirming revenue guidance of at least $580 million and updated Adjusted EBITDA guidance to at least $70 million for FY 2023.

Inotiv's Q1 2023 saw revenue growth driven by DSA and RMS segments, but a net loss of $86.9 million due to a goodwill impairment charge and increased expenses. The company is addressing challenges and aims for improved efficiency and margin expansion.

Inotiv's Q4 2022 revenue increased due to a rise in DSA revenue and incremental RMS revenue. However, the company reported a consolidated net loss, including a non-cash goodwill impairment charge related to the RMS segment.

Inotiv reported record revenues, Adjusted EBITDA, and backlog in Q3 2022, driven by organic growth, acquisitions, and favorable pricing. The company continued to expand its portfolio of services and progress its capacity expansion initiatives.

Inotiv reported a significant increase in revenue to $140.3 million, driven by growth in both DSA and RMS segments, alongside a substantial rise in adjusted EBITDA to $25.3 million. However, the company experienced a net loss attributable to common shareholders of $(6.1) million.

Inotiv reported a significant increase in revenue for Q1 2022, primarily driven by the acquisition of Envigo and growth in both DSA and RMS segments. The company experienced a substantial rise in total revenue, gross profit, and adjusted EBITDA, but also reported a net loss due to increased operating expenses, including stock compensation and fair value remeasurement of convertible notes.

Inotiv, Inc. reported a strong fourth quarter with a 90.7% increase in revenue to $30.1 million, driven by internal growth and acquisitions. Net income was $9.4 million, or $0.06 per diluted share, compared to a net loss of $(1.8) million, or $(0.16) per diluted share, in Q4 FY 2020. The company's strategic investments and acquisitions have positioned it for future growth.

Inotiv, Inc. reported a 45.2% increase in revenue to $22.9 million for Q3 FY 2021, driven by internal growth and acquisitions of HistoTox Labs and Bolder BioPATH. However, the company experienced a net loss of $2.3 million, or $(0.15) per diluted share, due to increased operating expenses related to strategic investments and acquisitions.

Inotiv, Inc. reported a 17.1% increase in revenue to $18.8 million for Q2 FY 2021, driven by internal growth, with service segment revenue increasing by 17.8% to $17.9 million. However, the company experienced a net loss of $(723,000), or $(0.06) per diluted share, due to increased investments in infrastructure and unallocated corporate expenses.

Inotiv reported a 38.5% increase in revenue, positive operating income, and $1.3 million in adjusted EBITDA for Q1 FY 2021. The company's unification under the Inotiv brand and client-service oriented culture drove performance, reflected in increasing revenue, a quarter-end backlog of $45.3 million, and a book-to-bill ratio of 1.16x.

Inotiv reported a 6.7% increase in revenue for the fourth quarter of fiscal year 2020, primarily driven by the PCRS acquisition. However, the company experienced a net loss due to increased costs associated with capacity expansion, infrastructure development, and general administrative expenses.

Inotiv reported a 45.2% increase in revenue for the third quarter of fiscal year 2020, driven by organic growth and acquisitions. However, the company experienced a net loss due to increased expenses from acquisitions and the impact of COVID-19, including program delays and inefficiencies.

Inotiv reported a 71.4% increase in revenue for the second quarter of fiscal year 2020, driven by organic growth and acquisitions. However, the company experienced a net loss of $588,000 due to increased costs associated with acquisitions and non-recurring expenses.

Inotiv, formerly Bioanalytical Systems, reported a 49.7% increase in revenue for the first quarter of fiscal 2020, driven by organic growth and acquisitions. However, the company experienced a net loss due to non-recurring acquisition and integration costs, refinancing, branding, recruiting, and consulting fees. The company's new orders remain strong, as demonstrated by the growth in customer deposits on the balance sheet.